<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02286934</url>
  </required_header>
  <id_info>
    <org_study_id>CYP-CVDL-01</org_study_id>
    <nct_id>NCT02286934</nct_id>
  </id_info>
  <brief_title>Cytochrome P450 2D6 Genotype on the Clinical Effect of Carvedilol</brief_title>
  <official_title>A Clinical Trial to Investigate the Influence of Cytochrome P450 2D6 Polymorphism on the Pharmacokinetic/Pharmacodynamics Characteristics of Carvedilol in Healthy Korean Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Food and Drug Safety Evaluation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Clinical Study to Evaluate the Effect of Cytochrome P450 2D6 polymorphism on
      Pharmacokinetics/Pharmacodynamics After Multiple Administration of Carvedilol
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study has an open-label, one-sequence, multiple drug administration design. The purpose
      of this study is as follows;

      To evaluate the change of the result of Isoproterenol Sensitivity Test according to
      Cytochrome P450 2D6 genotype after the multiple administration of carvedilol
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">November 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC (area under the plasma concentration-time curve) of carvedilol</measure>
    <time_frame>predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax (Maximum plasma concentration) of carvedilol</measure>
    <time_frame>predose and 0.25, 0.5, 1, 2, 3, 4, 6, 12, 24h postdose</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Carvedilol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1 to 3 : Carvedilol 12.5 mg qd
Day 4 to 8 : Carvedilol 25 mg qd
Day 9 to 11 : Carvedilol 12.5 mg qd
Isoproterenol Sensitivity Test
Day 0, 1.5h post-dose Injection of isoproterenol 4 times (0.25, 0.5, 1, 2 ug/mL), time interval of 10 minutes.
Day 1, 8, 1.5h post-dose Injection of isoproterenol 4 times (5, 10, 20, 40 ug/mL), time interval of 10 minutes.
Measure change of heart rates after 1, 2, 3 minutes post injection of isoproterenol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carvedilol</intervention_name>
    <description>Day 1 to 3 : Carvedilol 12.5 mg qd
Day 4 to 8 : Carvedilol 25 mg qd
Day 9 to 11 : Carvedilol 12.5 mg qd</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Isoproterenol Sensitivity Test</intervention_name>
    <description>Day 0, 1, 8 : Isoproterenol Sensitivity Test</description>
    <arm_group_label>Carvedilol</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Subjects aged 20 - 45 years

          -  A body mass index (BMI) in the range 18.0 kg/m2 (inclusive) - 27.0 kg/m2 (inclusive).

          -  Sufficient ability to understand the nature of the study and any hazards of
             participating in it. Provide written informed consent after being fully. informed
             about the study procedures.

        Exclusion Criteria:

          -  Presence or history of hypersensitivity or allergic reactions to drugs including
             investigational product (Carvedilol, Isoproterenol).

          -  Subject judged not eligible for study participation by investigator.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jae-Yong Chung, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam, Kore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam</city>
        <state>Gyounggi</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2014</study_first_submitted>
  <study_first_submitted_qc>November 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 10, 2014</study_first_posted>
  <last_update_submitted>June 2, 2015</last_update_submitted>
  <last_update_submitted_qc>June 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Jae Yong Chung</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Carvedilol</keyword>
  <keyword>CYP2D6</keyword>
  <keyword>Isoproterenol Sensitivity Test</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carvedilol</mesh_term>
    <mesh_term>Isoproterenol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

